⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TGTX News
TG Therapeutics, Inc.
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
globenewswire.com
TGTX
The Quest to Repair What Multiple Sclerosis Takes Away
globenewswire.com
QNTM
NVS
MRK
TGTX
BMY
Form 8-K
sec.gov
TGTX
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
globenewswire.com
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
globenewswire.com
TGTX
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
globenewswire.com
TGTX
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
globenewswire.com
TGTX
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
TGTX
Form 8-K
sec.gov
TGTX